Inactive Instrument

Company Translate Bio, Inc.

Equities

TBIO

US89374L1044

Biotechnology & Medical Research

Business Summary

Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell's own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Number of employees: 122

Managers

Managers TitleAgeSince
Treasurer - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 75,586,714 75,586,714 ( 100.00 %) 0 100.00 %

Company contact information

Translate Bio, Inc.

29 Hartwell Avenue

02421, Lexington

+

http://www.translate.bio
address Translate Bio, Inc.(TBIO)
  1. Stock Market
  2. Equities
  3. TBIO Stock
  4. Company Translate Bio, Inc.